Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by jopatcloon Jul 24, 2024 9:30am
96 Views
Post# 36145899

Interesting on Ascend Cardiovascular ! 👀 ( Collaboration )

Interesting on Ascend Cardiovascular ! 👀 ( Collaboration )Interesting   AI Echo For Heart Failure Detection
AI automated heart failure detection and classification from electronic health records
and  remember Ventripoint Announces Expansion of Collaboration with ASCEND Cardiovascular,
a Leading Provider of Cardiovascular IT Solutions Across North America
Toronto, Ontario – July 12, 2024
to remember on Ascend 
April 26, 2023
News | Artificial Intelligence | April 26, 2023

Ascend Cardiovascular Announces Partnership with Us2.ai to Bring an AI-assisted Echocardiography Integration to Cardiovascular Workflow

 
When integrated with InView, Ascends high-performance zero-footprint Cardiovascular viewer, Us2.ais FDA-cleared and CE Marked echocardiogram algorithms automate measurements and pre-populate structured report templates.

April 26, 2023Ascend Cardiovascular, a leader in cardiovascular structured reporting and workflow solutions is partnering with Us2.ai to add fully automated echocardiography analysis and CV disease detection reporting to its suite of seamlessly integrated cardiovascular image visualization and reporting solutions. 

When integrated with InView, Ascend’s high-performance zero-footprint Cardiovascular viewer, Us2.ai’s FDA-cleared and CE Marked echocardiogram algorithms automate measurements and pre-populate structured report templates. This transforms every day reading and reporting workflow by eliminating manual steps and improving the speed of coordination-of-care for patients with suspected heart disease, the leading cause of death worldwide. 

Ascend InView provides a highly effective, streamlined solution for echo, vascular, and cath viewing and reporting. Using Artificial Intelligence and Machine Learning technologies, InView’s Categorized Hanging Image Protocol (CHIP) analyzes and classifies images by modality and view to automatically organize current and prior images by anatomy and pathology categories. Added value is provided by synchronized navigation and population of structured reports, enabling a streamlined, smart, and highly effective workflow for echo reading and reporting. 

Us2.ai’s technology is a patented, automated clinical decision support workflow solution that recognizes and analyzes 2D and Doppler echo images for comprehensive cardiac measurements needed for the diagnosis, detection and prognosis of heart disease and pulmonary hypertension. Us2.ai’s software decreases the time from patient assessment to treatment initiation by expediting echocardiogram reporting and time-critical diagnostics in the acute and post-acute care phases. “This integration with Ascend brings a reliable and cost-efficient solution to cardiovascular care providers and patients that will drive efficiency, reduce costs, and ultimately improve patient care”, commented Seth Koeppel, Head of Business Development at Us2.ai. 

“The combination of Ascend’s AI-based image review and robust structured reporting with Us2.ai’s automated image analysis and interpretation truly transforms Cardiovascular workflow, making it more effective, efficient, and less variable than traditional, manual alternatives” says Dr. Jeff Soble, practicing Cardiologist and CEO of Ascend Cardiovascular. “This first-of-its kind integration demonstrates Ascend’s commitment to helping the provider community improve Cardiovascular care with complete workflow solutions”.  

For more information: www.ascendcv.com


<< Previous
Bullboard Posts
Next >>